Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

NDAQ:APLS - Post by User

Apellis Pharmaceuticals Inc

<< Previous

Bullboard Posts

Post by whytestockson Apr 10, 2024 4:15pm

29 Views

Post# 35982043

If You Invested $1000 In This Stock 5 Years Ago, You Would H

Breaking News: $APLS If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today | BenzingaApellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 11.97% on an annualized basis producing an average annua...APLS - If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today | Benzinga

<< Previous

Bullboard Posts

Nine Mile Metals completes acquisition of 3 properties